Amylyx Pharmaceuticals (AMLX) Competitors $8.18 +0.06 (+0.69%) As of 12:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMLX vs. IBRX, GMTX, ARWR, APLS, NAMS, TWST, DNLI, KNSA, AGIO, and RXRXShould you be buying Amylyx Pharmaceuticals stock or one of its competitors? The main competitors of Amylyx Pharmaceuticals include ImmunityBio (IBRX), Gemini Therapeutics (GMTX), Arrowhead Pharmaceuticals (ARWR), Apellis Pharmaceuticals (APLS), NewAmsterdam Pharma (NAMS), Twist Bioscience (TWST), Denali Therapeutics (DNLI), Kiniksa Pharmaceuticals International (KNSA), Agios Pharmaceuticals (AGIO), and Recursion Pharmaceuticals (RXRX). These companies are all part of the "pharmaceutical products" industry. Amylyx Pharmaceuticals vs. Its Competitors ImmunityBio Gemini Therapeutics Arrowhead Pharmaceuticals Apellis Pharmaceuticals NewAmsterdam Pharma Twist Bioscience Denali Therapeutics Kiniksa Pharmaceuticals International Agios Pharmaceuticals Recursion Pharmaceuticals Amylyx Pharmaceuticals (NASDAQ:AMLX) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership. Does the media prefer AMLX or IBRX? In the previous week, Amylyx Pharmaceuticals had 8 more articles in the media than ImmunityBio. MarketBeat recorded 11 mentions for Amylyx Pharmaceuticals and 3 mentions for ImmunityBio. Amylyx Pharmaceuticals' average media sentiment score of 0.77 beat ImmunityBio's score of 0.23 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is AMLX or IBRX more profitable? Amylyx Pharmaceuticals has a net margin of 0.00% compared to ImmunityBio's net margin of -1,310.30%. ImmunityBio's return on equity of 0.00% beat Amylyx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amylyx PharmaceuticalsN/A -77.21% -63.84% ImmunityBio -1,310.30%N/A -121.88% Do analysts rate AMLX or IBRX? Amylyx Pharmaceuticals currently has a consensus price target of $11.75, suggesting a potential upside of 43.71%. ImmunityBio has a consensus price target of $12.25, suggesting a potential upside of 344.65%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts clearly believe ImmunityBio is more favorable than Amylyx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amylyx Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00ImmunityBio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has preferable valuation and earnings, AMLX or IBRX? Amylyx Pharmaceuticals has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmylyx Pharmaceuticals$87.37M8.34-$301.74M-$3.11-2.63ImmunityBio$14.74M164.97-$413.56M-$0.58-4.75 Which has more risk and volatility, AMLX or IBRX? Amylyx Pharmaceuticals has a beta of -0.49, meaning that its stock price is 149% less volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 0.08, meaning that its stock price is 92% less volatile than the S&P 500. Do institutionals and insiders have more ownership in AMLX or IBRX? 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 11.7% of Amylyx Pharmaceuticals shares are held by insiders. Comparatively, 76.8% of ImmunityBio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryAmylyx Pharmaceuticals beats ImmunityBio on 10 of the 17 factors compared between the two stocks. Get Amylyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMLX vs. The Competition Export to ExcelMetricAmylyx PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$724.26M$2.43B$5.56B$9.26BDividend YieldN/A1.79%4.23%4.03%P/E Ratio-2.619.1428.5819.56Price / Sales8.34711.83434.47183.65Price / CashN/A164.3436.0257.93Price / Book3.414.658.165.58Net Income-$301.74M$30.99M$3.24B$257.82M7 Day Performance12.93%-0.08%-0.64%-0.39%1 Month Performance50.29%7.08%4.93%7.80%1 Year Performance246.44%-6.56%26.04%12.95% Amylyx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMLXAmylyx Pharmaceuticals3.3839 of 5 stars$8.18+0.7%$11.75+43.7%+275.9%$724.26M$87.37M-2.61200IBRXImmunityBio2.1419 of 5 stars$2.72flat$12.25+350.4%-56.9%$2.40B$31.22M-4.69590GMTXGemini TherapeuticsN/A$54.75+3.0%N/A+22.4%$2.37BN/A-54.7530News CoverageARWRArrowhead Pharmaceuticals3.5551 of 5 stars$16.84+0.3%$43.71+159.6%-38.9%$2.33B$3.55M-12.03400News CoverageAPLSApellis Pharmaceuticals4.2319 of 5 stars$17.42-4.6%$39.79+128.4%-51.6%$2.19B$781.37M-9.73770News CoverageAnalyst ForecastAnalyst RevisionNAMSNewAmsterdam Pharma2.7421 of 5 stars$19.46-2.0%$42.89+120.4%+7.3%$2.18B$45.56M-10.354TWSTTwist Bioscience4.1837 of 5 stars$35.59-6.8%$50.40+41.6%-35.2%$2.13B$312.97M-10.95990DNLIDenali Therapeutics4.6079 of 5 stars$14.25-3.0%$33.71+136.6%-39.3%$2.07B$330.53M-5.34430Positive NewsKNSAKiniksa Pharmaceuticals International3.5027 of 5 stars$27.95+0.3%$38.80+38.8%+30.0%$2.04B$481.17M-111.80220Positive NewsUpcoming EarningsAGIOAgios Pharmaceuticals4.3842 of 5 stars$35.21-2.4%$58.60+66.4%-16.5%$2.04B$36.50M3.13390News CoverageAnalyst RevisionRXRXRecursion Pharmaceuticals1.8114 of 5 stars$4.93-6.5%$7.00+42.0%-36.3%$2.00B$59.82M-2.79400High Trading Volume Related Companies and Tools Related Companies ImmunityBio Competitors Gemini Therapeutics Competitors Arrowhead Pharmaceuticals Competitors Apellis Pharmaceuticals Competitors NewAmsterdam Pharma Competitors Twist Bioscience Competitors Denali Therapeutics Competitors Kiniksa Pharmaceuticals International Competitors Agios Pharmaceuticals Competitors Recursion Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMLX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
